Clinical Trial

Real-World Effectiveness of Nirsevimab Against RSV-Related and All-Cause Respiratory Tract Infections in Chinese Infants

Completed
View on ClinicalTrials.gov →
Summary
A multicenter, retrospective cohort study based on clinical data from seven tertiary hospitals in China will be undertaken. The study aims to evaluate the real-world effectiveness of Nirsevimab in preventing Respiratory Syncytial Virus (RSV) infections and all-cause respiratory infections. Clinical records will be used to compare outcomes between infants who received Nirsevimab and a control group. The study focuses on infants aged 0 to 1 year during the RSV season.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-25.
Trial Details
NCT Number NCT07382219
Lead Sponsor Han Tongyan
Conditions RSV Infections, Lower Respiratory Tract Infections
Enrollment 816 participants
Start Date 2025-08-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-03